ORIGINAL RESEARCH article
Front. Immunol.
Sec. Vaccines and Molecular Therapeutics
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1621939
Risk of Developing Juvenile Idiopathic Arthritis After Quadrivalent HPV Vaccination: A Retrospective Cohort Study Using the TriNetX U.S. Network
Provisionally accepted- Taichung Veterans General Hospital, Taichung, Taiwan
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: Human papillomavirus (HPV) infection has been implicated in autoimmune processes, yet concerns remain about the potential autoimmune risks of HPV vaccination. Juvenile idiopathic arthritis (JIA) is a chronic autoimmune condition that typically manifests in childhood. The relationship between HPV vaccination and the development of JIA remains uncertain.We conducted a retrospective cohort study using data from the TriNetX U.S. Collaborative Network. Females aged 9-13 years were included. Three analyses were performed: (1) comparing HPV4-vaccinated vs. unvaccinated matched cohorts; (2) a stricter comparison excluding subjects with positive ANA; (3) comparing single vs. multiple HPV4 doses. Propensity score matching and Cox proportional hazards models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs).In Analysis 1 (n=55,257 pairs) and Analysis 2 (n=53,827 pairs), the HPV4-vaccinated groups showed significantly reduced rates of JIA from 12 to 36 months post-vaccination (HR range: 0.33-0.52). No difference in JIA risk was observed between single and multiple doses in Analysis 3 (n=20,822 pairs). Early-onset JIA (<6 months after HPV4 vaccine) showed inconsistent trends, with only limited protective signals.Our findings suggest that HPV4 vaccination is not associated with an increased risk of JIA. On the contrary, vaccination may confer a long-term protective effect against new-onset JIA, observable from 6-12 months and lasting for at least 3 years. These findings support the safety and possible immunoregulatory benefit of HPV4 in adolescents.
Keywords: Quadrivalent human papillomavirus vaccine (HPV4 vaccine), juvenile idiopathic arthritis, TriNetX, vaccine safety, cohort study
Received: 02 May 2025; Accepted: 04 Aug 2025.
Copyright: © 2025 WU, Chen, Tsai, Huang, Chen and Fu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Lin-Shien Fu, Taichung Veterans General Hospital, Taichung, Taiwan
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.